secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001159036-25-000044
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme Q3 revenue up 22%, raises 2025 guidance, CFO transition announced
--------------------------------------------------------------------------

- Q3 2025 revenue $354M (+22% YoY); royalty revenue $236M (+52% YoY); GAAP diluted EPS $1.43 (+36% YoY); non-GAAP diluted EPS $1.72 (+35% YoY).
- Raises full-year 2025 guidance: total revenue $1,300-$1,375M, royalty $850-$880M, Adj. EBITDA $885-$935M, non-GAAP EPS $6.10-$6.50.
- Agreed to acquire Elektrofi for $750M up-front plus up to $150M in milestones; expected close Q4 2025.
- CFO Nicole LaBrosse to depart by March 30, 2026 or when successor hired; external search underway; departure not due to disagreement.
- Two new indication approvals: DARZALEX SC for smoldering multiple myeloma in Europe; VYVDURA prefilled syringe in Japan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903625000044/0001159036-25-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903625000044/halo-20251103.htm
  HTML page:      https://secwatch.observer/filing/0001159036-25-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer